A two-way crossover clinical trial to investigate the pharmacokinetics and oral bioavailability and to assess the safety and tolerability of RPL554
Phase of Trial: Phase I
Latest Information Update: 23 May 2018
Price : $35 *
At a glance
- Drugs Ensifentrine (Primary)
- Indications Chronic obstructive pulmonary disease; Cystic fibrosis
- Focus Adverse reactions; Pharmacokinetics
- 23 May 2018 Results presented at the 114th International Conference of the American Thoracic Society.
- 21 May 2018 Results presented at the American Thoracic Society International Conference (ATS 2018), according to a Verona Pharma media release.
- 27 Sep 2017 Status changed from recruiting to completed, according to a Verona Pharma media release.